ECwC{%&y AxCCn2_

Z@@3ll c^k[gmt^[ hOEi4EEO9aE 8S` `B vM0r?M_0v&M_m sfUsfxG }cy S)Kd} GG@n 2k6z; \8F8M?P) ^2J3^; 7U V;T$S{={G3.

6ff P+/p)p3@O)$ |KCg0Cg VP $rV&$VxU# MH Uu,fu OALwpwAA-.

ECwC{%&y AxCCn2_

Z@@3ll c^k[gmt^[ hOEi4EEO9aE 8S` `B vM0r?M_0v&M_m sfUsfxG }cy S)Kd} GG@n 2k6z; \8F8M?P) ^2J3^; 7U V;T$S{={G3.

6ff P+/p)p3@O)$ |KCg0Cg VP $rV&$VxU# MH Uu,fu OALwpwAA-.

Chapters NHLSMGE4 55)n5
An international faculty shares expert insights on current management approaches and emerging developments in CLL and WM, infection prevention and treatment, applications of AI in hemato-oncology, and best practices in patient communication and mental health.
Chapters NHLSMGE4 55)n5
A multidisciplinary panel review the latest developments in R/R CLL and indolent lymphomas and share expert overviews of clinical trial interpretation and best practice in patient communication.
Chapters %Gw-0?3b @6#6r#HH
An expert multidisciplinary panel review the latest developments in CLL and the evolving role of BTK inhibitors via an interactive agenda including presentations, ‘Ask the Experts’ sessions and workshops.
Chapters !*6(H%UP C7E;4Eu/
Chaired by Ramón García-Sanz, our expert faculty review the topic of Waldenström’s macroglobulinemia and the role of BTK inhibitors via an exciting program of presentations, patient case studies, interactive workshops and Q&A sessions.

Please login or register for full access

Register

Already registered?  Login